Skip to main navigation
  • Back to SpringWorksTx.com
  • Investors & Media
  • Contact Us
  • Linkedin
  • Twitter
SpringWorks
  • Overview
  • News & Events
    • Press Releases
    • Events & Presentations
  • Corporate Governance
  • Financial Information
    • SEC Filings
    • Annual Reports
  • Stock Information
    • Stock Quote & Chart
    • Analyst Coverage
  • Investor Resources
    • Investor FAQs
    • Investor Contacts
    • Email Alerts
  • Investors + Media
  • Medical Professionals
  • Contact Us
  • Linkedin
  • Twitter

Investor Relations

The full potential of targeted oncology is waiting to be unlocked.

Corporate Profile

SpringWorks Therapeutics is a commercial-stage biopharmaceutical company applying a precision medicine approach to acquiring, developing, and commercializing life-changing medicines to help patients suffering from devastating cancers live longer, better lives.
View Corporate Presentation

Minimum 15 minutes delayed. Source:

Press Releases

05 Nov 2024
SpringWorks Therapeutics to Participate in Guggenheim’s Inaugural Healthcare Innovation Conference
22 Oct 2024
SpringWorks Therapeutics to Report Third Quarter 2024 Financial Results on Tuesday, November 12, 2024
28 Aug 2024
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
07 Aug 2024
SpringWorks Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights
View All

Upcoming Events

Guggenheim’s Inaugural Healthcare Innovation Conference
Nov 13, 2024 at 1:00 PM EST
SpringWorks Therapeutics Q3 2024 Earnings Conference Call
Nov 12, 2024 at 8:30 AM EST
View All Events

Featured Reports & Presentations

OGSIVEO™ FDA Approval Call Presentation 3.8 MB
ReNeu Topline Results Presentation 1.5 MB

Media Fact Sheets

Desmoid Tumor Media Fact Sheet 218.1 KB
OGSIVEO (nirogacestat) Media Fact Sheet 164.3 KB

Featured Pages

Blue background
Corporate Governance
Corporate Governance
Teal Background
Financial Information
Financial Information
Blue background
Stock Information
Stock Information
Teal Background
Investor Resources
Investor Resources

Springworks - Toolkits

  • Print Page
  • Email Alerts
  • RSS Feeds
  • Investor Contacts

Springworks Logo

Social Links

  • linkedin
  • twitter
Footer 1
  • Who We Are
    • Leadership & Board
    • Mission & Values
    • DE&I
    • Partners & Collaborators
  • Focus Areas
    • Rare Oncology
    • BCMA Combinations in Multiple Myeloma
    • Biomarker-Defined Metastatic Solid Tumors
Footer 2
  • Pipeline
    • Nirogacestat
    • Mirdametinib
    • Clinical Trials
    • Investigator-Initiated Research
    • Key Scientific Presentations and Publications
  • Careers
    • View Opportunities
Footer 3
  • Patients
    • Desmoid Tumors
    • NF1-PN
    • Expanded Access
  • Contact
Footer 4
  • Investors & Media
    • Press Releases
    • Events & Presentations
    • Corporate Governance
    • Financial Information
    • Stock Information
    • Investor Resources

© 2024 SpringWorks Therapeutics. All rights reserved.

Copyright Links

  • Privacy Policy
  • Terms of Use
  • Cookie Policy